Welcome to the e-CCO Library!

search
Search by: 
Year: Category: Sub Type:
DOP51: Investigation on the role of Par4-associated cell polarity and associated barrier defects in Inflammatory Bowel Diseases
Year: 2020
Source: ECCO'20 Vienna
Authors: Federica Branchi
Created: Tuesday, 23 June 2020, 5:40 PM
DOP51: Mucosa-associated microbial signatures associate with objective response prior to the start of anti-TNFα but not vedolizumab or ustekinumab in Crohn’s disease patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ishtu Hageman
Created: Friday, 14 July 2023, 2:22 PM
DOP51: Risk of kidney failure in patients with Inflammatory Bowel Disease undergoing colectomy: a nationwide cohort study
Year: 2024
Source: ECCO'24 Stockholm
Authors: Yang, Yuanhang
Created: Tuesday, 30 April 2024, 5:03 PM
DOP52: Guselkumab improves symptoms of fatigue in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR induction study results at Week 12
Year: 2024
Source: ECCO'24 Stockholm
Authors: Dignass, Axel
Created: Tuesday, 30 April 2024, 5:03 PM
DOP52: The faecal bacterial and fungal microbiome of newly-diagnosed, treatment naïve children with Crohn’s disease and the modifying effects of exclusive enteral nutrition and re-introduction of habitual diet
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Konstantinos Gerasimidis
Created: Friday, 14 July 2023, 2:22 PM
DOP52: The phenotype of NOD-scid IL-2Rγnull mice reconstituted with peripheral blood mononuclear cells from patients with Crohn’s Disease or Ulcerative Colitis reflects the respective disease
Year: 2020
Source: ECCO'20 Vienna
Authors: Anna Unterweger
Created: Tuesday, 23 June 2020, 5:40 PM
DOP53: Community types of the human gut virome are associated with endoscopic outcome in UC patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Daan Jansen
Created: Friday, 14 July 2023, 2:22 PM
DOP53: Long-term Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease up to 3 Years of Treatment: Results From the FORTIFY Open-Label Long-term Extension
Year: 2024
Source: ECCO'24 Stockholm
Authors: Ferrante, Marc
Created: Tuesday, 30 April 2024, 5:03 PM
DOP54: Guselkumab and golimumab combination induction therapy in Ulcerative Colitis results in early local tissue healing that is sustained through guselkumab maintenance therapy
Year: 2024
Source: ECCO'24 Stockholm
Authors: Atreya, Raja
Created: Tuesday, 30 April 2024, 5:03 PM
DOP54: Integrated network analysis using patient-specific single nucleotide polymorphism profiles uncovers new pathways involved in Ulcerative Colitis pathogenesis
Year: 2020
Source: ECCO'20 Vienna
Authors: Dezso Modos
Created: Tuesday, 23 June 2020, 5:40 PM
DOP54: Time to effect of biologics and small molecules for patients with moderately to severely active luminal Crohn’s disease – a systematic review and network meta-analysis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Mohamed Attauabi
Created: Friday, 14 July 2023, 2:22 PM
DOP55: A real-world comparison of the effectiveness and safety of vedolizumab and anti-TNF therapies in early treatment initiation with first-line biologic therapy in Ulcerative Colitis: Results from EVOLVE
Year: 2020
Source: ECCO'20 Vienna
Authors: Gerassimos Mantzaris
Created: Tuesday, 23 June 2020, 5:40 PM
DOP55: High diagnostic accuracy of 4-probe methylation biomarkers in paediatric Inflammatory Bowel Disease by epigenome-wide analysis
Year: 2024
Source: ECCO'24 Stockholm
Authors: Noble, Alexandra
Created: Tuesday, 30 April 2024, 5:03 PM
DOP55: The increasing burden of direct and indirect costs of IBD
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Johan Burisch
Created: Friday, 14 July 2023, 2:22 PM
DOP56: Fibrosis-related transcriptome unveils a distinctive matrix remodelling pattern in penetrating but not in stricturing ileal Crohn's Disease
Year: 2024
Source: ECCO'24 Stockholm
Authors: Tavares de Sousa, Helena
Created: Tuesday, 30 April 2024, 5:03 PM
DOP56: Long-term disease progression and resective surgery rates in Crohn’s disease over different therapeutic eras – a population-based study from western Hungary between 1977–2020, data from the Veszprem county cohort
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Péter Laszlo Lakatos
Created: Friday, 14 July 2023, 2:22 PM
DOP56: Ustekinumab maintained clinically meaningful improvement in health-related quality of life in patients with moderate to severe Ulcerative Colitis: Results from the UNIFI long-term extension
Year: 2020
Source: ECCO'20 Vienna
Authors: William Sandborn
Created: Tuesday, 23 June 2020, 5:40 PM
DOP57: Cystic fibrosis risk variants confer a protective effect against Inflammatory Bowel Disease in large-scale exome sequencing analysis
Year: 2024
Source: ECCO'24 Stockholm
Authors: Sazonovs, Aleksejs
Created: Tuesday, 30 April 2024, 5:03 PM
DOP57: GLP-1 based therapies and risk of Inflammatory Bowel Disease: real world evidence from a nationwide cohort study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Heidi Soegaard Christensen
Created: Friday, 14 July 2023, 2:22 PM
DOP57: Vedolizumab has similar efficacy rates in young and elderly patients: A binational, multicenter, retrospective case-control study
Year: 2020
Source: ECCO'20 Vienna
Authors: Nathaniel Aviv Cohen
Created: Tuesday, 23 June 2020, 5:40 PM